I-131 phospholipid remains in bilateral pulmonary tumors for days
CONTEXT: NM404 is a second-generation radioiodinated phospholipid ether analog that undergoes prolonged and selective retention in a wide variety of malignant tumors in animal models. The compound takes advantage of an apparent lack of metabolic alkyl cleavage enzyme activity in tumor cells relative to normal cells. The aim of this project was to examine the tumor uptake and retention properties of NM404 in human non-small cell lung cancer (NSCLC).
RESULTS: Iodine-131-labeled NM404 was injected into patients with advanced NSCLC. The patients were scanned with a dual-head SPECT scanner at three, six, 24, 48, and 96 hours and at seven and 11 days. Qualitative imaging results indicated that I-131-labeled NM404 clearly localizes in bilateral pulmonary masses as early as 24 hours after injection and is selectively retained in the tumors for more than 11 days. Background radioactivity in the liver and lower abdominal region was significantly less than was observed previously with the predecessor agent NM324. No adverse reactions occurred in any of the patients.
IMPLICATIONS: The findings suggest that NM404 exhibits tumor uptake and retention properties in human NSCLC similar to those seen previously in rodent models. Efforts are under way to extend the utility of NM404 to PET imaging by incorporation with I-124, a positron isotope with a four-day half-life. Because of the selective and prolonged retention of NM404 in tumor cells, studies also are evaluating the radiotherapeutic potential of the agent.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
